# Apoptosis through Death Receptors in Temporal Lobe Epilepsy-Associated Hippocampal Sclerosis

Authors: Marcelo Ananias Teocchi; Lília D’Souza-Li
Journal: Mediators of Inflammation
 (2016)

---

## Abstract

Seizure models have demonstrated that neuroinflammation and neurodegeneration are preponderant characteristics of epilepsy. Considering the lack of clinical studies, our aim is to investigate the extrinsic pathway of apoptosis in pharmacoresistant temporal lobe epilepsy (TLE) associated with hippocampal sclerosis (HS) patients, TLE(HS). By a specific death receptor-mediated apoptosis array plate, 31 upregulated targets were revealed in the sclerotic hippocampus from TLE(HS) patients. Amongst them are the encoding genes for ligands (FASLG,TNF,andTNFSF10) and death receptors (FAS,TNFRSF1A,TNFRSF10A,andTNFRSF10B). In addition, we evaluated the hippocampal relative mRNA expression of the two TNF receptors,TNFRSF1AandTNFRSF1B, in patients, being both upregulated (n=14; P<0.01 and P<0.04, resp.) when compared to thepost mortemcontrol group (n=4). Our results have clearly suggested that three different death receptor apoptotic systems may be associated with the maintenance and progression of TLE-associated HS: (1) TNF-TNFRSF1A, (2) FASLG-FAS, and (3) TNFSF10-TNFRSF10A/B. Their effects on epilepsy are still scarcely comprehended. Our study points out to TNF and TNF receptor superfamily pathways as important targets for pharmacological studies regarding the benefits of an anti-inflammatory therapy in these patients.


---

## Body

## 1. Introduction

The connection between neurodegeneration and inflammation in the epileptic brain has emerged as an important axis for the comprehension of the pathomechanisms involved in seizure associated neuronal cell death. Hippocampal sclerosis (HS) is the main pathohistological abnormality found in resected tissue from temporal lobe epilepsy (TLE) patients. It is characterized by astrogliosis: an irregular proliferation of astrocytes due to the apoptosis of nearby neurons [1]. Several studies assert that inflammation has a crucial role in epileptogenesis [2], and there is a high probability that hippocampal chronic inflammation could exacerbate astrogliosis in TLE patients.Apoptosis is divided into two main specific pathways: intrinsic and extrinsic. In spite of requesting particular triggers to start a cascade of molecular events, both pathways converge in the activation of CASP3, and both are present in TLE-associated HS. The apoptotic intrinsic signaling pathways are initiated by non-receptor-mediated intracellular signals (e.g., DNA damage, radiation) that result in changes in the inner mitochondrial membrane. Seizures by themselves can represent an interesting example of these kinds of signals. One of the primary events in hippocampal seizure-induced apoptosis is the excessive release of glutamate with consequent intracellular calcium overload, culminating in downstream swelling and rupture of intracellular organelles and activated proteolytic enzymes leading to cell death [3].Unlike the intrinsic signaling pathways that initiate apoptosis, the extrinsic signaling pathways involve transmembrane receptor-mediated interactions. These include death receptors which are members of the TNF receptor gene superfamily [4]. Apoptotic or survival signals are the consequence of the death receptor family activation by death ligands. Various members of this family have been described thus far, including TNFRSF1A, FAS, TNFRSF25, TNFRSF10A, TNFRSF10B, and TNFRSF21 [5]. The execution pathway can be initiated by these receptors through CASP8 or CASP10 whose activation could trigger the proapoptotic proteins BID or BAX, via TP53, culminating in a cross talk with the mitochondrial or intrinsic pathway of apoptosis [4].Recurrent seizures induce not only neuronal cell loss but also inflammation [6]. However, neuronal cell loss is not a prerequisite for inflammation to happen; rather, the liberation of proinflammatory cytokines can contribute to cell death [7], and dying cells may perpetuate inflammation [6]. Previously, we reported a marked TNF upregulation in TLE(HS) patients [8], which is indicative of chronic hippocampal inflammation.We believe that the neuronal apoptosis through death receptor pathways highlights the key molecular events involved in triggering astrogliosis and TLE-associated HS. Understanding which are the soluble mediators and the molecular mechanisms crucially involved in the link between inflammation and neuronal cell death is instrumental to shed light on how seizures may contribute to HS in epilepsy and to identify new therapeutic targets for the treatment and cure of pharmacoresistant epilepsy, particularly in TLE(HS) patients.


## 2. Methods

### 2.1. Subjects and Tissue Collection

Ethical approval was certified by the “Comitê de Ética da Faculdade de Ciências Médicas da Unicamp” (CEP n 470/2003). Subjects’ data was reported in a recent study [8]. The present study was performed with the same patient andpost mortem control samples. Briefly, TLE and HS were detected by telemetry/video electroencephalogram and magnetic resonance image, respectively, in 14 patients. Due to the pharmacoresistance of the syndrome, they went through an amygdalohippocampectomy for treatment. All hippocampal tissue samples were immediately collected and divided into two parts. One portion was fixed for histopathological analysis and HS/astrogliosis was confirmed in all of them [H&E staining and the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay; data not shown]. The second portion was immediately snap-frozen in liquid nitrogen after surgery and stored at −80°C until RNA isolation.Fourpost mortem control hippocampal tissue samples (1 female, 3 males; 22.75±5.56 years old, ranging from 19 to 31) were kindly provided by the “Instituto Médico Legal, IML” (Forensic Institute) of Campinas.Post mortem control subjects passed away instantaneously or quickly. Although their deaths were traumatic, which runs against the occurrence and progression of neuroinflammation, neurological findings were not detected and thepost mortem delay averaged 7.8 h (range: 6.0–9.0 h).


### 2.2. Gene Expression

All reagents were purchased from Thermo Fisher Scientific Inc.; Waltham, MA 02451, USA (former Life Technologies; Foster City, CA 94404, USA).


#### 2.2.1. RNA Extraction, Array Gene Expression, and RT-qPCR

Total RNA extraction and RT-qPCR were carried out according to our previous work [8]. TRIzol® Reagent was used for RNA extraction according to the manufacturer’s instructions. The RNA integrity number (RIN) average in control and patient groups was 7.525±0.5437 and 6.155±0.2484, respectively. Afterwards, 1 μg of total RNA of each sample was reverse transcribed into cDNA using 200 U of Superscript® III Reverse Transcriptase and 3 μg of Random Primers. Sterilized and filtered DEPC treated water was used in all RNA procedures.To identify potential targets associated with apoptosis through death receptor signaling, we used a TaqMan® Array Human Apoptosis through death receptors 96-well plate (PN: 4414105). The plate contained 44 assays of genes associated with death receptor-mediated apoptosis and four assays of reference gene (endogenous control) candidates (Table 1). Gene names are in accordance with the approved symbol from the HUGO Gene Nomenclature Committee (HGNC) database. All assays were plated in duplicates: one for cDNA pooled from the TLE(HS) patients (n=12) versus the other for cDNA pooled from thepost mortem controls (n=4). Among several factors which can influence CT (cycle threshold) and consequently qPCR results credibility, we emphasized instrument calibration and cDNA quality. The template concentration (e.g., concentration of total RNA converted to cDNA) should always be homogeneous among samples, particularly when working with pools. cDNA concentration and purity were assessed by spectrophotometry (NanoDrop ND1000; NanoDrop Technologies, Wilmington, DE). The cDNA concentration means were 858.1±30.07 and 871.9±27.10 for control and patient samples, respectively. cDNA absorbance (A260/A280) ranged from 1.84 to 1.90 considering all 16 samples. Reactions were carried out according to manufacturer’s instructions. We used a total volume of 20 μL, comprising 10 μL of TaqMan Gene Expression Master Mix (Life Technologies) and 10 μL of pooled cDNA diluted in DNase-free water. The final concentration of the pooled cDNA samples used was 10 ng in 10 μL for each 20 μL PCR reaction.Table 1
Array target genes: apoptosis through death receptors in TLE(HS).
Target genes
Symbol, approved name, and Assay ID
Synonyms and aliases
Function
RQ
ACTA1actin, alpha 1, skeletal muscleHs00559403_m1
NEM3, “nemaline myopathy type 3”
Cell motility
1.12
ACTBactin, betaHs99999903_m1
Cell motility
1.74
APAF1apoptotic peptidase activating factor 1Hs00559441_m1
APAF-1, CED4
Apoptosis induction by CASP3 activation
1.59
BAXBCL2-associated X proteinHs00180269_m1
BCL2L4
Apoptosis induction by CASP3 activation
1.50
BCL2B-cell CLL/lymphoma 2Hs99999018_m1
Bcl-2, PPP1R50, “protein phosphatase 1, and regulatory subunit 50”
Apoptosis inhibition
1.87
BIDBH3 interacting domain death agonistHs00609632_m1
Apoptosis induction
1.40
BIRC2baculoviral IAP repeat containing 2Hs01112284_m1
“Apoptosis inhibitor 1”, c-IAP1, cIAP1, hiap-2, MIHB, “NFR2-TRAF signalling complex protein”, and RNF48
Apoptosis inhibition
1.31
BIRC3baculoviral IAP repeat containing 3Hs00154109_m1
“Apoptosis inhibitor 2”, c-IAP2, cIAP2, hiap-1, “inhibitor of apoptosis protein 1”, MALT2, “mammalian IAP homolog C”, MIHC, RNF49, and “TNFR2-TRAF signaling complex protein”
Apoptosis inhibition
1.27
CASP2caspase 2Hs00234982_m1
ICH1, MGC2181, PPP1R57, and “protein phosphatase 1, regulatory subunit 57”
Involved in the activation cascade of caspases responsible for apoptosis execution
1.38
CASP3caspase 3Hs00234387_m1
Apopain, CPP32, CPP32B, and Yama
Involved in the activation cascade of caspases responsible for apoptosis execution
1.44
CASP7caspase 7Hs00169152_m1
CMH-1, ICE-LAP3, and MCH3
Involved in the activation cascade of caspases responsible for apoptosis execution; overexpression promotes programmed cell death
2.13
CASP8caspase 8Hs01018151_m1
Casp-8, FLICE, MACH, and MCH5
Most upstream protease of the activation cascade of caspases responsible for the FAS mediated and TNFRSF1A induced cell death
2.45
CASP9caspase 9Hs00154260_m1
APAF-3, ICE-LAP6, MCH6, PPP1R56, and “protein phosphatase 1, regulatory subunit 56”
Involved in the activation cascade of caspases responsible for apoptosis execution
1.55
CFLARCASP8 and FADD like apoptosis regulatorHs01116280_m1
c-FLIP, CASH, Casper, CLARP, FLAME, FLIP, I-FLICE, and MRIT
Apoptosis regulator protein as FAS mediated apoptosis inhibitor
1.59
CHUKconserved helix-loop-helix ubiquitous kinaseHs00175141_m1
IKBKA, IKK-alpha, IKK1, IKKA, and NFKBIKA
Serine kinase. Essential role in the NFkB signaling pathway
1.22
DAXXdeath-domain associated proteinHs00154692_m1
DAP6
JNK pathway and apoptosis mediator via MAP3K5 [FAS and TGFBR2 (transforming growth factor beta receptor II) signaling]
1.53
DIABLOdiablo, IAP-binding mitochondrial proteinHs00219876_m1
DFNA64, DIABLO-S, FLJ10537, FLJ25049, “second mitochondria-derived activator of caspase”, and SMAC
Apoptosis promoter by caspase activation in the cytochrome c/APAF1/CASP9 pathway
1.45
FADDFas associated via death domainHs00538709_m1
“Fas-associating death domain-containing protein,” “Fas-associating protein with death domain,” GIG3, “growth-inhibiting gene 3 protein,” “mediator of receptor-induced toxicity,” and MORT1
CASP8 and CASP10 apoptotic adaptor recruiter to activated FAS and TNFRSF1A
1.13
FASFas cell surface death receptorHs00531110_m1
APO-1, CD95, and “TNF receptor superfamily member 6”
Receptor with death domain for FASLG
1.65
FASLGFas ligandHs00181225_m1
CD178, FasL
Cytokine ligand for FAS
5.46
IKBKBinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase betaHs00233287_m1
IKK-beta, IKK2, IKKB, and NFKBIKB
NFkB activator
1.96
IKBKGinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gammaHs00415849_m1
FIP-3, FIP3, Fip3p, IKK-gamma, NEMO, and ZC2HC9
NFkB activator
1.65
MAP3K5mitogen-activated protein kinase kinase kinase 5Hs00178726_m1
“Apoptosis signal regulating kinase 1,” ASK1, and MAPKKK5
Signal transduction mediator by oxidative stress and receptor-mediated inflammatory signals (TNF)
1.55
MAPK8mitogen-activated protein kinase 8Hs01548508_m1
JNK, JNK1, “JUN N-terminal kinase,” and SAPK1
Stressed cell apoptosis promoter through TP53 and YAP1
1.05
MAPK9mitogen-activated protein kinase 9Hs00177102_m1
JNK2, “Jun kinase,” p54a, and SAPK
Stressed cell apoptosis promoter through TP53 and YAP1
0.86
NFKB1nuclear factor of kappa light polypeptide gene enhancer in B-cells 1Hs00765730_m1
KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, and p50
Rel protein-specific transcription inhibitor (105 kD) and DNA binding subunit of the transcription factor NFkB (50 kD)
1.50
NFKB2nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)Hs00174517_m1
LYT-10, NF-kB2, p105, and p52
Subunit of the transcription factor NFkB
3.21
NFKBIAnuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaHs00153283_m1
IkappaBalpha, IKBA, and MAD-3
NFkB inhibitor
2.36
NGFnerve growth factor (beta polypeptide)Hs01113193_m1
Ligand for NTRK1 and NGFR; neuronal proliferation, differentiation and survival regulator
0.90
NGFRnerve growth factor receptorHs00609976_m1
CD271, “low affinity nerve growth factor receptor,” p75NTR, “TNFR superfamily, member 16,” and TNFRSF16
Neural cell death or survival mediator
3.53
PARP1poly(ADP-ribose) polymerase 1Hs00242302_m1
PARP
DNA repair pathway initiation; apoptosis promoter in response to genotoxic stress
1.51
RELAv-rel avian reticuloendotheliosis viral oncogene homolog AHs00153294_m1
p65
Subunit of the transcription factor NFkB
2.02
TNFtumor necrosis factorHs00174128_m1
DIF, “TNF superfamily, member 2,” TNF-alpha, and TNFSF2
Multifunctional proinflammatory cytokine ligand for TNFRSF1A and TNFRSF1B
39.96
TNFRSF10Atumor necrosis factor receptor superfamily member 10aHs00269492_m1
Apo2, CD261, DR4, and TRAILR-1
Receptor with death domain for TNFSF10; NFkB activator
2.39
TNFRSF10Btumor necrosis factor receptor superfamily member 10bHs00366278_m1
CD262, DR5, KILLER, TRAIL-R2, TRICK2A, and TRICKB
Receptor with death domain for TNFSF10; ER stress-induced apoptosis promoter; NFkB activator
1.55
TNFRSF10Ctumor necrosis factor receptor superfamily member 10cHs00182570_m1
CD263, DcR1, LIT, TRAILR3, and TRID
Decoy receptor for TNFSF10; apoptosis inhibitor
4.82
TNFRSF10Dtumor necrosis factor receptor superfamily member 10dHs00533560_m1
CD264, DcR2, TRAILR4, and TRUNDD
Decoy receptor for TNFSF10; apoptosis inhibitor
3.74
TNFRSF1Atumor necrosis factor receptor superfamily member 1AHs00205419_m1
CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, and TNFR60
Receptor with death domain for TNF and LTA (lymphotoxin alpha); NFkB activator, apoptosis mediator, and inflammation regulator
3.07
TNFRSF21tumor necrosis factor receptor superfamily member 21Hs00237054_m1
CD358, “death receptor 6,” and DR6
Receptor with death domain; apoptosis promoter
1.09
TNFRSF25tumor necrosis factor receptor superfamily member 25Hs00187070_m1
APO-3, DDR3, DR3, LARD, TR3, TRAMP, WSL-1, and WSL-LR
Receptor with death domain for TNFSF12; mediator of NFkB activation and apoptosis promoter
1.72
TNFRSF6Btumor necrosis factor receptor superfamily member 6bHs00234356_m1
DcR3, DCR3, M68, and TR6
Decoy receptor for FASLG; apoptosis inhibitor
2.54
TNFSF10tumor necrosis factor superfamily member 10Hs00174664_m1
Apo-2L, CD253, TL2, and TRAIL
Cytokine ligand for TNFRSF10A, TNFRSF10B, TNFRSF10C, and TNFRSF10D
2.50
TP53tumor protein p53Hs01034249_m1
LFS1, “Li-Fraumeni syndrome,” and p53
Tumor suppressor, growth arrest, or apoptosis promoter depending on the physiological circumstances and cell type
2.77
TRAF2TNF receptor associated factor 2Hs00184192_m1
TRAP3
Mediator of the antiapoptotic signals from TNF receptors; NFkB and JNK activation regulator
1.54
List of all target genes investigated in the array, involved in the extrinsic apoptotic pathway. The gene expression data [relative quantification (RQ) column], also shown in Figure1, corresponds to the cDNA pooled from TLE(HS) patients (n=12) versus the cDNA pooled from post mortem controls (n=4). The latter was used as a calibrator with gene expression equal to 1.0. The values in the table can be converted to fold change values, where the negative inverse (−1/x) is taken for values between 0 and 1 (e.g., 0.5 is converted to −2). Values greater than 1 will not be affected. A −2 value indicates that the molecule is 2-fold downregulated. Only MAPK9 and NGF were downregulated. The reference gene candidates in the plate were 18S (eukaryotic 18S rRNA; Hs99999901_s1), GAPDH (glyceraldehyde-3-phosphate dehydrogenase; Hs99999905_m1), GUSB (glucuronidase, beta; Hs99999909_m1), and HPRT1 (hypoxanthine phosphoribosyltransferase 1; Hs99999908_m1) although only GAPDH and HPRT1 were effectively used as reference genes (in combination).Two target genes were chosen to be tested separately by subject:TNFRSF1A andTNFRSF1B (Assay ID: Hs00153550_m1). The latter was not included in the array plate. The PCR efficiency validation was also performed according to our previous work [8]. The amplification efficiencies were close to 1.0 (100%). cDNA samples derived from the investigated genes were detected using an ABI PRISM® 7500 Sequence Detection system and TaqMan Gene Expression Assays. For RT-qPCRs, reference genes were selected according to Wierschke et al. [9]. Therefore,HPRT1 and the geometric mean ofENO2 andTBP were used as our normalization factors. Both were indicated as being the most stable reference genes in epileptogenic tissue [9]. Each qPCR was run as triplicates with 10 ng cDNA sample in 6.25 μL TaqMan Gene Expression Master Mix, 0.625 μL of the respective probe/primer mix and 0.625 μL purified and deionized H2O. All reactions were run as triplicates, and measurements with a difference of more than 0.3 CT-values were excluded from analysis.


### 2.3. Data Analysis

Relative gene expression data was generated and analyzed by the 7500 Software version 2.0.5 (Life Technologies). The software GraphPad Prism 5 was used for the statistical analysis (GraphPad Prism version 5.04 for Windows, GraphPad Software, San Diego California USA,〈http://www.graphpad.com〉). The Mann-Whitney U test was used for comparison between data from the control group (n=4) versus the patient group (n=14). For all analyses, differences of P<0.05 were considered significant.A molecular pathway related to differentially expressed genes was created by the IPA-Ingenuity Pathway Analysis (Ingenuity Systems,〈http://www.ingenuity.com〉) application via the “Core Analysis” function. The array data sheet generated by the 7500 Software was uploaded into the IPA application. The differentially expressed genes were connected based on the reported association among genes or proteins and their functional roles.


## 2.1. Subjects and Tissue Collection

Ethical approval was certified by the “Comitê de Ética da Faculdade de Ciências Médicas da Unicamp” (CEP n 470/2003). Subjects’ data was reported in a recent study [8]. The present study was performed with the same patient andpost mortem control samples. Briefly, TLE and HS were detected by telemetry/video electroencephalogram and magnetic resonance image, respectively, in 14 patients. Due to the pharmacoresistance of the syndrome, they went through an amygdalohippocampectomy for treatment. All hippocampal tissue samples were immediately collected and divided into two parts. One portion was fixed for histopathological analysis and HS/astrogliosis was confirmed in all of them [H&E staining and the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay; data not shown]. The second portion was immediately snap-frozen in liquid nitrogen after surgery and stored at −80°C until RNA isolation.Fourpost mortem control hippocampal tissue samples (1 female, 3 males; 22.75±5.56 years old, ranging from 19 to 31) were kindly provided by the “Instituto Médico Legal, IML” (Forensic Institute) of Campinas.Post mortem control subjects passed away instantaneously or quickly. Although their deaths were traumatic, which runs against the occurrence and progression of neuroinflammation, neurological findings were not detected and thepost mortem delay averaged 7.8 h (range: 6.0–9.0 h).


## 2.2. Gene Expression

All reagents were purchased from Thermo Fisher Scientific Inc.; Waltham, MA 02451, USA (former Life Technologies; Foster City, CA 94404, USA).


### 2.2.1. RNA Extraction, Array Gene Expression, and RT-qPCR

Total RNA extraction and RT-qPCR were carried out according to our previous work [8]. TRIzol® Reagent was used for RNA extraction according to the manufacturer’s instructions. The RNA integrity number (RIN) average in control and patient groups was 7.525±0.5437 and 6.155±0.2484, respectively. Afterwards, 1 μg of total RNA of each sample was reverse transcribed into cDNA using 200 U of Superscript® III Reverse Transcriptase and 3 μg of Random Primers. Sterilized and filtered DEPC treated water was used in all RNA procedures.To identify potential targets associated with apoptosis through death receptor signaling, we used a TaqMan® Array Human Apoptosis through death receptors 96-well plate (PN: 4414105). The plate contained 44 assays of genes associated with death receptor-mediated apoptosis and four assays of reference gene (endogenous control) candidates (Table 1). Gene names are in accordance with the approved symbol from the HUGO Gene Nomenclature Committee (HGNC) database. All assays were plated in duplicates: one for cDNA pooled from the TLE(HS) patients (n=12) versus the other for cDNA pooled from thepost mortem controls (n=4). Among several factors which can influence CT (cycle threshold) and consequently qPCR results credibility, we emphasized instrument calibration and cDNA quality. The template concentration (e.g., concentration of total RNA converted to cDNA) should always be homogeneous among samples, particularly when working with pools. cDNA concentration and purity were assessed by spectrophotometry (NanoDrop ND1000; NanoDrop Technologies, Wilmington, DE). The cDNA concentration means were 858.1±30.07 and 871.9±27.10 for control and patient samples, respectively. cDNA absorbance (A260/A280) ranged from 1.84 to 1.90 considering all 16 samples. Reactions were carried out according to manufacturer’s instructions. We used a total volume of 20 μL, comprising 10 μL of TaqMan Gene Expression Master Mix (Life Technologies) and 10 μL of pooled cDNA diluted in DNase-free water. The final concentration of the pooled cDNA samples used was 10 ng in 10 μL for each 20 μL PCR reaction.Table 1
Array target genes: apoptosis through death receptors in TLE(HS).
Target genes
Symbol, approved name, and Assay ID
Synonyms and aliases
Function
RQ
ACTA1actin, alpha 1, skeletal muscleHs00559403_m1
NEM3, “nemaline myopathy type 3”
Cell motility
1.12
ACTBactin, betaHs99999903_m1
Cell motility
1.74
APAF1apoptotic peptidase activating factor 1Hs00559441_m1
APAF-1, CED4
Apoptosis induction by CASP3 activation
1.59
BAXBCL2-associated X proteinHs00180269_m1
BCL2L4
Apoptosis induction by CASP3 activation
1.50
BCL2B-cell CLL/lymphoma 2Hs99999018_m1
Bcl-2, PPP1R50, “protein phosphatase 1, and regulatory subunit 50”
Apoptosis inhibition
1.87
BIDBH3 interacting domain death agonistHs00609632_m1
Apoptosis induction
1.40
BIRC2baculoviral IAP repeat containing 2Hs01112284_m1
“Apoptosis inhibitor 1”, c-IAP1, cIAP1, hiap-2, MIHB, “NFR2-TRAF signalling complex protein”, and RNF48
Apoptosis inhibition
1.31
BIRC3baculoviral IAP repeat containing 3Hs00154109_m1
“Apoptosis inhibitor 2”, c-IAP2, cIAP2, hiap-1, “inhibitor of apoptosis protein 1”, MALT2, “mammalian IAP homolog C”, MIHC, RNF49, and “TNFR2-TRAF signaling complex protein”
Apoptosis inhibition
1.27
CASP2caspase 2Hs00234982_m1
ICH1, MGC2181, PPP1R57, and “protein phosphatase 1, regulatory subunit 57”
Involved in the activation cascade of caspases responsible for apoptosis execution
1.38
CASP3caspase 3Hs00234387_m1
Apopain, CPP32, CPP32B, and Yama
Involved in the activation cascade of caspases responsible for apoptosis execution
1.44
CASP7caspase 7Hs00169152_m1
CMH-1, ICE-LAP3, and MCH3
Involved in the activation cascade of caspases responsible for apoptosis execution; overexpression promotes programmed cell death
2.13
CASP8caspase 8Hs01018151_m1
Casp-8, FLICE, MACH, and MCH5
Most upstream protease of the activation cascade of caspases responsible for the FAS mediated and TNFRSF1A induced cell death
2.45
CASP9caspase 9Hs00154260_m1
APAF-3, ICE-LAP6, MCH6, PPP1R56, and “protein phosphatase 1, regulatory subunit 56”
Involved in the activation cascade of caspases responsible for apoptosis execution
1.55
CFLARCASP8 and FADD like apoptosis regulatorHs01116280_m1
c-FLIP, CASH, Casper, CLARP, FLAME, FLIP, I-FLICE, and MRIT
Apoptosis regulator protein as FAS mediated apoptosis inhibitor
1.59
CHUKconserved helix-loop-helix ubiquitous kinaseHs00175141_m1
IKBKA, IKK-alpha, IKK1, IKKA, and NFKBIKA
Serine kinase. Essential role in the NFkB signaling pathway
1.22
DAXXdeath-domain associated proteinHs00154692_m1
DAP6
JNK pathway and apoptosis mediator via MAP3K5 [FAS and TGFBR2 (transforming growth factor beta receptor II) signaling]
1.53
DIABLOdiablo, IAP-binding mitochondrial proteinHs00219876_m1
DFNA64, DIABLO-S, FLJ10537, FLJ25049, “second mitochondria-derived activator of caspase”, and SMAC
Apoptosis promoter by caspase activation in the cytochrome c/APAF1/CASP9 pathway
1.45
FADDFas associated via death domainHs00538709_m1
“Fas-associating death domain-containing protein,” “Fas-associating protein with death domain,” GIG3, “growth-inhibiting gene 3 protein,” “mediator of receptor-induced toxicity,” and MORT1
CASP8 and CASP10 apoptotic adaptor recruiter to activated FAS and TNFRSF1A
1.13
FASFas cell surface death receptorHs00531110_m1
APO-1, CD95, and “TNF receptor superfamily member 6”
Receptor with death domain for FASLG
1.65
FASLGFas ligandHs00181225_m1
CD178, FasL
Cytokine ligand for FAS
5.46
IKBKBinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase betaHs00233287_m1
IKK-beta, IKK2, IKKB, and NFKBIKB
NFkB activator
1.96
IKBKGinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gammaHs00415849_m1
FIP-3, FIP3, Fip3p, IKK-gamma, NEMO, and ZC2HC9
NFkB activator
1.65
MAP3K5mitogen-activated protein kinase kinase kinase 5Hs00178726_m1
“Apoptosis signal regulating kinase 1,” ASK1, and MAPKKK5
Signal transduction mediator by oxidative stress and receptor-mediated inflammatory signals (TNF)
1.55
MAPK8mitogen-activated protein kinase 8Hs01548508_m1
JNK, JNK1, “JUN N-terminal kinase,” and SAPK1
Stressed cell apoptosis promoter through TP53 and YAP1
1.05
MAPK9mitogen-activated protein kinase 9Hs00177102_m1
JNK2, “Jun kinase,” p54a, and SAPK
Stressed cell apoptosis promoter through TP53 and YAP1
0.86
NFKB1nuclear factor of kappa light polypeptide gene enhancer in B-cells 1Hs00765730_m1
KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, and p50
Rel protein-specific transcription inhibitor (105 kD) and DNA binding subunit of the transcription factor NFkB (50 kD)
1.50
NFKB2nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)Hs00174517_m1
LYT-10, NF-kB2, p105, and p52
Subunit of the transcription factor NFkB
3.21
NFKBIAnuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaHs00153283_m1
IkappaBalpha, IKBA, and MAD-3
NFkB inhibitor
2.36
NGFnerve growth factor (beta polypeptide)Hs01113193_m1
Ligand for NTRK1 and NGFR; neuronal proliferation, differentiation and survival regulator
0.90
NGFRnerve growth factor receptorHs00609976_m1
CD271, “low affinity nerve growth factor receptor,” p75NTR, “TNFR superfamily, member 16,” and TNFRSF16
Neural cell death or survival mediator
3.53
PARP1poly(ADP-ribose) polymerase 1Hs00242302_m1
PARP
DNA repair pathway initiation; apoptosis promoter in response to genotoxic stress
1.51
RELAv-rel avian reticuloendotheliosis viral oncogene homolog AHs00153294_m1
p65
Subunit of the transcription factor NFkB
2.02
TNFtumor necrosis factorHs00174128_m1
DIF, “TNF superfamily, member 2,” TNF-alpha, and TNFSF2
Multifunctional proinflammatory cytokine ligand for TNFRSF1A and TNFRSF1B
39.96
TNFRSF10Atumor necrosis factor receptor superfamily member 10aHs00269492_m1
Apo2, CD261, DR4, and TRAILR-1
Receptor with death domain for TNFSF10; NFkB activator
2.39
TNFRSF10Btumor necrosis factor receptor superfamily member 10bHs00366278_m1
CD262, DR5, KILLER, TRAIL-R2, TRICK2A, and TRICKB
Receptor with death domain for TNFSF10; ER stress-induced apoptosis promoter; NFkB activator
1.55
TNFRSF10Ctumor necrosis factor receptor superfamily member 10cHs00182570_m1
CD263, DcR1, LIT, TRAILR3, and TRID
Decoy receptor for TNFSF10; apoptosis inhibitor
4.82
TNFRSF10Dtumor necrosis factor receptor superfamily member 10dHs00533560_m1
CD264, DcR2, TRAILR4, and TRUNDD
Decoy receptor for TNFSF10; apoptosis inhibitor
3.74
TNFRSF1Atumor necrosis factor receptor superfamily member 1AHs00205419_m1
CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, and TNFR60
Receptor with death domain for TNF and LTA (lymphotoxin alpha); NFkB activator, apoptosis mediator, and inflammation regulator
3.07
TNFRSF21tumor necrosis factor receptor superfamily member 21Hs00237054_m1
CD358, “death receptor 6,” and DR6
Receptor with death domain; apoptosis promoter
1.09
TNFRSF25tumor necrosis factor receptor superfamily member 25Hs00187070_m1
APO-3, DDR3, DR3, LARD, TR3, TRAMP, WSL-1, and WSL-LR
Receptor with death domain for TNFSF12; mediator of NFkB activation and apoptosis promoter
1.72
TNFRSF6Btumor necrosis factor receptor superfamily member 6bHs00234356_m1
DcR3, DCR3, M68, and TR6
Decoy receptor for FASLG; apoptosis inhibitor
2.54
TNFSF10tumor necrosis factor superfamily member 10Hs00174664_m1
Apo-2L, CD253, TL2, and TRAIL
Cytokine ligand for TNFRSF10A, TNFRSF10B, TNFRSF10C, and TNFRSF10D
2.50
TP53tumor protein p53Hs01034249_m1
LFS1, “Li-Fraumeni syndrome,” and p53
Tumor suppressor, growth arrest, or apoptosis promoter depending on the physiological circumstances and cell type
2.77
TRAF2TNF receptor associated factor 2Hs00184192_m1
TRAP3
Mediator of the antiapoptotic signals from TNF receptors; NFkB and JNK activation regulator
1.54
List of all target genes investigated in the array, involved in the extrinsic apoptotic pathway. The gene expression data [relative quantification (RQ) column], also shown in Figure1, corresponds to the cDNA pooled from TLE(HS) patients (n=12) versus the cDNA pooled from post mortem controls (n=4). The latter was used as a calibrator with gene expression equal to 1.0. The values in the table can be converted to fold change values, where the negative inverse (−1/x) is taken for values between 0 and 1 (e.g., 0.5 is converted to −2). Values greater than 1 will not be affected. A −2 value indicates that the molecule is 2-fold downregulated. Only MAPK9 and NGF were downregulated. The reference gene candidates in the plate were 18S (eukaryotic 18S rRNA; Hs99999901_s1), GAPDH (glyceraldehyde-3-phosphate dehydrogenase; Hs99999905_m1), GUSB (glucuronidase, beta; Hs99999909_m1), and HPRT1 (hypoxanthine phosphoribosyltransferase 1; Hs99999908_m1) although only GAPDH and HPRT1 were effectively used as reference genes (in combination).Two target genes were chosen to be tested separately by subject:TNFRSF1A andTNFRSF1B (Assay ID: Hs00153550_m1). The latter was not included in the array plate. The PCR efficiency validation was also performed according to our previous work [8]. The amplification efficiencies were close to 1.0 (100%). cDNA samples derived from the investigated genes were detected using an ABI PRISM® 7500 Sequence Detection system and TaqMan Gene Expression Assays. For RT-qPCRs, reference genes were selected according to Wierschke et al. [9]. Therefore,HPRT1 and the geometric mean ofENO2 andTBP were used as our normalization factors. Both were indicated as being the most stable reference genes in epileptogenic tissue [9]. Each qPCR was run as triplicates with 10 ng cDNA sample in 6.25 μL TaqMan Gene Expression Master Mix, 0.625 μL of the respective probe/primer mix and 0.625 μL purified and deionized H2O. All reactions were run as triplicates, and measurements with a difference of more than 0.3 CT-values were excluded from analysis.


## 2.2.1. RNA Extraction, Array Gene Expression, and RT-qPCR

Total RNA extraction and RT-qPCR were carried out according to our previous work [8]. TRIzol® Reagent was used for RNA extraction according to the manufacturer’s instructions. The RNA integrity number (RIN) average in control and patient groups was 7.525±0.5437 and 6.155±0.2484, respectively. Afterwards, 1 μg of total RNA of each sample was reverse transcribed into cDNA using 200 U of Superscript® III Reverse Transcriptase and 3 μg of Random Primers. Sterilized and filtered DEPC treated water was used in all RNA procedures.To identify potential targets associated with apoptosis through death receptor signaling, we used a TaqMan® Array Human Apoptosis through death receptors 96-well plate (PN: 4414105). The plate contained 44 assays of genes associated with death receptor-mediated apoptosis and four assays of reference gene (endogenous control) candidates (Table 1). Gene names are in accordance with the approved symbol from the HUGO Gene Nomenclature Committee (HGNC) database. All assays were plated in duplicates: one for cDNA pooled from the TLE(HS) patients (n=12) versus the other for cDNA pooled from thepost mortem controls (n=4). Among several factors which can influence CT (cycle threshold) and consequently qPCR results credibility, we emphasized instrument calibration and cDNA quality. The template concentration (e.g., concentration of total RNA converted to cDNA) should always be homogeneous among samples, particularly when working with pools. cDNA concentration and purity were assessed by spectrophotometry (NanoDrop ND1000; NanoDrop Technologies, Wilmington, DE). The cDNA concentration means were 858.1±30.07 and 871.9±27.10 for control and patient samples, respectively. cDNA absorbance (A260/A280) ranged from 1.84 to 1.90 considering all 16 samples. Reactions were carried out according to manufacturer’s instructions. We used a total volume of 20 μL, comprising 10 μL of TaqMan Gene Expression Master Mix (Life Technologies) and 10 μL of pooled cDNA diluted in DNase-free water. The final concentration of the pooled cDNA samples used was 10 ng in 10 μL for each 20 μL PCR reaction.Table 1
Array target genes: apoptosis through death receptors in TLE(HS).
Target genes
Symbol, approved name, and Assay ID
Synonyms and aliases
Function
RQ
ACTA1actin, alpha 1, skeletal muscleHs00559403_m1
NEM3, “nemaline myopathy type 3”
Cell motility
1.12
ACTBactin, betaHs99999903_m1
Cell motility
1.74
APAF1apoptotic peptidase activating factor 1Hs00559441_m1
APAF-1, CED4
Apoptosis induction by CASP3 activation
1.59
BAXBCL2-associated X proteinHs00180269_m1
BCL2L4
Apoptosis induction by CASP3 activation
1.50
BCL2B-cell CLL/lymphoma 2Hs99999018_m1
Bcl-2, PPP1R50, “protein phosphatase 1, and regulatory subunit 50”
Apoptosis inhibition
1.87
BIDBH3 interacting domain death agonistHs00609632_m1
Apoptosis induction
1.40
BIRC2baculoviral IAP repeat containing 2Hs01112284_m1
“Apoptosis inhibitor 1”, c-IAP1, cIAP1, hiap-2, MIHB, “NFR2-TRAF signalling complex protein”, and RNF48
Apoptosis inhibition
1.31
BIRC3baculoviral IAP repeat containing 3Hs00154109_m1
“Apoptosis inhibitor 2”, c-IAP2, cIAP2, hiap-1, “inhibitor of apoptosis protein 1”, MALT2, “mammalian IAP homolog C”, MIHC, RNF49, and “TNFR2-TRAF signaling complex protein”
Apoptosis inhibition
1.27
CASP2caspase 2Hs00234982_m1
ICH1, MGC2181, PPP1R57, and “protein phosphatase 1, regulatory subunit 57”
Involved in the activation cascade of caspases responsible for apoptosis execution
1.38
CASP3caspase 3Hs00234387_m1
Apopain, CPP32, CPP32B, and Yama
Involved in the activation cascade of caspases responsible for apoptosis execution
1.44
CASP7caspase 7Hs00169152_m1
CMH-1, ICE-LAP3, and MCH3
Involved in the activation cascade of caspases responsible for apoptosis execution; overexpression promotes programmed cell death
2.13
CASP8caspase 8Hs01018151_m1
Casp-8, FLICE, MACH, and MCH5
Most upstream protease of the activation cascade of caspases responsible for the FAS mediated and TNFRSF1A induced cell death
2.45
CASP9caspase 9Hs00154260_m1
APAF-3, ICE-LAP6, MCH6, PPP1R56, and “protein phosphatase 1, regulatory subunit 56”
Involved in the activation cascade of caspases responsible for apoptosis execution
1.55
CFLARCASP8 and FADD like apoptosis regulatorHs01116280_m1
c-FLIP, CASH, Casper, CLARP, FLAME, FLIP, I-FLICE, and MRIT
Apoptosis regulator protein as FAS mediated apoptosis inhibitor
1.59
CHUKconserved helix-loop-helix ubiquitous kinaseHs00175141_m1
IKBKA, IKK-alpha, IKK1, IKKA, and NFKBIKA
Serine kinase. Essential role in the NFkB signaling pathway
1.22
DAXXdeath-domain associated proteinHs00154692_m1
DAP6
JNK pathway and apoptosis mediator via MAP3K5 [FAS and TGFBR2 (transforming growth factor beta receptor II) signaling]
1.53
DIABLOdiablo, IAP-binding mitochondrial proteinHs00219876_m1
DFNA64, DIABLO-S, FLJ10537, FLJ25049, “second mitochondria-derived activator of caspase”, and SMAC
Apoptosis promoter by caspase activation in the cytochrome c/APAF1/CASP9 pathway
1.45
FADDFas associated via death domainHs00538709_m1
“Fas-associating death domain-containing protein,” “Fas-associating protein with death domain,” GIG3, “growth-inhibiting gene 3 protein,” “mediator of receptor-induced toxicity,” and MORT1
CASP8 and CASP10 apoptotic adaptor recruiter to activated FAS and TNFRSF1A
1.13
FASFas cell surface death receptorHs00531110_m1
APO-1, CD95, and “TNF receptor superfamily member 6”
Receptor with death domain for FASLG
1.65
FASLGFas ligandHs00181225_m1
CD178, FasL
Cytokine ligand for FAS
5.46
IKBKBinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase betaHs00233287_m1
IKK-beta, IKK2, IKKB, and NFKBIKB
NFkB activator
1.96
IKBKGinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gammaHs00415849_m1
FIP-3, FIP3, Fip3p, IKK-gamma, NEMO, and ZC2HC9
NFkB activator
1.65
MAP3K5mitogen-activated protein kinase kinase kinase 5Hs00178726_m1
“Apoptosis signal regulating kinase 1,” ASK1, and MAPKKK5
Signal transduction mediator by oxidative stress and receptor-mediated inflammatory signals (TNF)
1.55
MAPK8mitogen-activated protein kinase 8Hs01548508_m1
JNK, JNK1, “JUN N-terminal kinase,” and SAPK1
Stressed cell apoptosis promoter through TP53 and YAP1
1.05
MAPK9mitogen-activated protein kinase 9Hs00177102_m1
JNK2, “Jun kinase,” p54a, and SAPK
Stressed cell apoptosis promoter through TP53 and YAP1
0.86
NFKB1nuclear factor of kappa light polypeptide gene enhancer in B-cells 1Hs00765730_m1
KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, and p50
Rel protein-specific transcription inhibitor (105 kD) and DNA binding subunit of the transcription factor NFkB (50 kD)
1.50
NFKB2nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)Hs00174517_m1
LYT-10, NF-kB2, p105, and p52
Subunit of the transcription factor NFkB
3.21
NFKBIAnuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaHs00153283_m1
IkappaBalpha, IKBA, and MAD-3
NFkB inhibitor
2.36
NGFnerve growth factor (beta polypeptide)Hs01113193_m1
Ligand for NTRK1 and NGFR; neuronal proliferation, differentiation and survival regulator
0.90
NGFRnerve growth factor receptorHs00609976_m1
CD271, “low affinity nerve growth factor receptor,” p75NTR, “TNFR superfamily, member 16,” and TNFRSF16
Neural cell death or survival mediator
3.53
PARP1poly(ADP-ribose) polymerase 1Hs00242302_m1
PARP
DNA repair pathway initiation; apoptosis promoter in response to genotoxic stress
1.51
RELAv-rel avian reticuloendotheliosis viral oncogene homolog AHs00153294_m1
p65
Subunit of the transcription factor NFkB
2.02
TNFtumor necrosis factorHs00174128_m1
DIF, “TNF superfamily, member 2,” TNF-alpha, and TNFSF2
Multifunctional proinflammatory cytokine ligand for TNFRSF1A and TNFRSF1B
39.96
TNFRSF10Atumor necrosis factor receptor superfamily member 10aHs00269492_m1
Apo2, CD261, DR4, and TRAILR-1
Receptor with death domain for TNFSF10; NFkB activator
2.39
TNFRSF10Btumor necrosis factor receptor superfamily member 10bHs00366278_m1
CD262, DR5, KILLER, TRAIL-R2, TRICK2A, and TRICKB
Receptor with death domain for TNFSF10; ER stress-induced apoptosis promoter; NFkB activator
1.55
TNFRSF10Ctumor necrosis factor receptor superfamily member 10cHs00182570_m1
CD263, DcR1, LIT, TRAILR3, and TRID
Decoy receptor for TNFSF10; apoptosis inhibitor
4.82
TNFRSF10Dtumor necrosis factor receptor superfamily member 10dHs00533560_m1
CD264, DcR2, TRAILR4, and TRUNDD
Decoy receptor for TNFSF10; apoptosis inhibitor
3.74
TNFRSF1Atumor necrosis factor receptor superfamily member 1AHs00205419_m1
CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, and TNFR60
Receptor with death domain for TNF and LTA (lymphotoxin alpha); NFkB activator, apoptosis mediator, and inflammation regulator
3.07
TNFRSF21tumor necrosis factor receptor superfamily member 21Hs00237054_m1
CD358, “death receptor 6,” and DR6
Receptor with death domain; apoptosis promoter
1.09
TNFRSF25tumor necrosis factor receptor superfamily member 25Hs00187070_m1
APO-3, DDR3, DR3, LARD, TR3, TRAMP, WSL-1, and WSL-LR
Receptor with death domain for TNFSF12; mediator of NFkB activation and apoptosis promoter
1.72
TNFRSF6Btumor necrosis factor receptor superfamily member 6bHs00234356_m1
DcR3, DCR3, M68, and TR6
Decoy receptor for FASLG; apoptosis inhibitor
2.54
TNFSF10tumor necrosis factor superfamily member 10Hs00174664_m1
Apo-2L, CD253, TL2, and TRAIL
Cytokine ligand for TNFRSF10A, TNFRSF10B, TNFRSF10C, and TNFRSF10D
2.50
TP53tumor protein p53Hs01034249_m1
LFS1, “Li-Fraumeni syndrome,” and p53
Tumor suppressor, growth arrest, or apoptosis promoter depending on the physiological circumstances and cell type
2.77
TRAF2TNF receptor associated factor 2Hs00184192_m1
TRAP3
Mediator of the antiapoptotic signals from TNF receptors; NFkB and JNK activation regulator
1.54
List of all target genes investigated in the array, involved in the extrinsic apoptotic pathway. The gene expression data [relative quantification (RQ) column], also shown in Figure1, corresponds to the cDNA pooled from TLE(HS) patients (n=12) versus the cDNA pooled from post mortem controls (n=4). The latter was used as a calibrator with gene expression equal to 1.0. The values in the table can be converted to fold change values, where the negative inverse (−1/x) is taken for values between 0 and 1 (e.g., 0.5 is converted to −2). Values greater than 1 will not be affected. A −2 value indicates that the molecule is 2-fold downregulated. Only MAPK9 and NGF were downregulated. The reference gene candidates in the plate were 18S (eukaryotic 18S rRNA; Hs99999901_s1), GAPDH (glyceraldehyde-3-phosphate dehydrogenase; Hs99999905_m1), GUSB (glucuronidase, beta; Hs99999909_m1), and HPRT1 (hypoxanthine phosphoribosyltransferase 1; Hs99999908_m1) although only GAPDH and HPRT1 were effectively used as reference genes (in combination).Two target genes were chosen to be tested separately by subject:TNFRSF1A andTNFRSF1B (Assay ID: Hs00153550_m1). The latter was not included in the array plate. The PCR efficiency validation was also performed according to our previous work [8]. The amplification efficiencies were close to 1.0 (100%). cDNA samples derived from the investigated genes were detected using an ABI PRISM® 7500 Sequence Detection system and TaqMan Gene Expression Assays. For RT-qPCRs, reference genes were selected according to Wierschke et al. [9]. Therefore,HPRT1 and the geometric mean ofENO2 andTBP were used as our normalization factors. Both were indicated as being the most stable reference genes in epileptogenic tissue [9]. Each qPCR was run as triplicates with 10 ng cDNA sample in 6.25 μL TaqMan Gene Expression Master Mix, 0.625 μL of the respective probe/primer mix and 0.625 μL purified and deionized H2O. All reactions were run as triplicates, and measurements with a difference of more than 0.3 CT-values were excluded from analysis.


## 2.3. Data Analysis

Relative gene expression data was generated and analyzed by the 7500 Software version 2.0.5 (Life Technologies). The software GraphPad Prism 5 was used for the statistical analysis (GraphPad Prism version 5.04 for Windows, GraphPad Software, San Diego California USA,〈http://www.graphpad.com〉). The Mann-Whitney U test was used for comparison between data from the control group (n=4) versus the patient group (n=14). For all analyses, differences of P<0.05 were considered significant.A molecular pathway related to differentially expressed genes was created by the IPA-Ingenuity Pathway Analysis (Ingenuity Systems,〈http://www.ingenuity.com〉) application via the “Core Analysis” function. The array data sheet generated by the 7500 Software was uploaded into the IPA application. The differentially expressed genes were connected based on the reported association among genes or proteins and their functional roles.


## 3. Results

Array gene expression quantifications are shown in Table1 and Figure 1. From 44 target genes associated with apoptosis through death receptors, we found 31 upregulated genes (70.45%). Our criterion to define an upregulated gene was based on an increase of a minimum of 50% on mRNA levels in comparison to controls, which corresponds to a cutoff of 1.5-fold change. Choosing a precise cutoff is always a challenge in array studies and it is crucial to analyze results and select the most important targets. Considering our previous study onNFKB1 expression in the same group of TLE(HS) patients (n=14) [8], a 1.5 cutoff is statistically acceptable since theNFKB1 expression in the array was exactly 1.5-fold.Figure 1
Hippocampal expression of genes associated with apoptosis through death receptors in TLE(HS) patients versuspost mortem controls. The combination ofGAPDH andHPRT1 was used as the reference gene. The pool ofpost mortem control samples (n=4) was the reference sample (calibrator) and its relative quantification (RQ) was always 1.0. Different colors represent gene expression in RQ values (or fold-change values, when RQ is a positive number) and correspond to the following parameters: red = very upregulated (RQ ≥ 2.0); orange = upregulated (1.99 ≥ RQ ≥ 1.5); gray = normal (1.49 ≥ RQ ≥ 0.67). None of the 44 target genes analyzed was downregulated (0.66 ≥ RQ ≥ 0.51) or very downregulated (RQ ≤ 0.5).The number of upregulated genes is narrowed to 15 if a cutoff of 2.0 is considered (at least an augmentation of 100% on mRNA levels). This more conservative cutoff reveals critical target genes that can be divided into 3 categories: (1) ligands and receptors, (2) mediators, and (3) molecules related to the transcription factor nuclear factor kappa B (NFkB). Discussion will be guided by these categories and focused on the controversies and novelties related to these most upregulated targets.Regardless of the cutoff or even the reference genes, arrayTNF expression (39.96-fold) was very meaningful, particularly in comparison to the expression of the other genes. This significant overregulation led us to quantify separately the expression of its receptors,TNFRSF1A andTNFRSF1B, being both statistically upregulated (P<0.01 and P<0.04, resp.) (Figure 2). In Figure 3, we proposed a schematic pathway which involves TNF, TNFRSF1A, and eight of the other 13 very upregulated genes.Figure 2
Hippocampal gene expression ofTNFRSF1A andTNFRSF1B in TLE(HS) patients versuspost mortem controls.HPRT1 andENO2/TBP were used as reference genes. One of thepost mortem control samples was randomly chosen as the reference and its relative quantification was always 1.0. All quantification data for the remaining samples, including controls and patients, was benchmarked to the reference sample. Samples were separated in two groups: TLE(HS) patients (n=14) andpost mortem controls (n=4). (a) Columns are means with SD. Mann-Whitney U tests were used for the comparison between groups. P∗<0.05; P∗∗<0.01. (b) Marks are different geometric figures, which represent the gene expression mean of the samples. The horizontal line is the mean of the group analyzed. Circles and squares correspond to gene expression withHPRT1 as the reference. The two kinds of triangles correspond to gene expression withENO2/TBP as the reference. The red and green squares (outliers) correspond to TLE 09 and TLE 03 patients, respectively (see Table  1 in Teocchi et al., 2013 [8]).
(a)
(b)Figure 3
Apoptosis through death receptors: a signaling pathway in TLE(HS). This pathway was generated by the IPA software, based on 10 of the 15 upregulated genes (cutoff 2.0-fold change; see Table1) in hippocampal tissues from TLE(HS) patients (n=12) compared topost mortem controls (n=4). The biological relationship between two genes, represented as nodes, is shown as a line. Nodes with different shapes indicate different functional class. The pathway created did not include the following genes:NFKB2,NGFR,TNFSF10,TNFRSF10C, andTNFSF10D. The function “nervous relaxed” was used. A, activation; E, expression regulation; I, inhibition; L, proteolysis; LO, localization; M, biochemical modification; P, phosphorylation; PD, protein-DNA interaction; PP, protein-protein interaction; RB, regulation of binding; T, transcription; and TR, translocation.


## 4. Discussion

Inflammation, degeneration of neurons and HS are closely related [10]. Recently, we reported a markedTNF upregulation in TLE(HS) patients [8], which is indicative of chronic hippocampal inflammation. The importance of this cytokine as one of the main apoptosis “propellers” in TLE-associated HS is reinforced by our Human Apoptosis through death receptors array results (Table 1 and Figure 1) which show the upregulation of 31 related genes. They are associated with the extrinsic apoptosis signaling pathway, among them members of the TNF and TNF receptor gene superfamilies and several factors which play a role in the cell death cascade. The vast majority of them have never been quantified in patient’s samples. Below, we present and discuss our finding which suggests the involvement of these genes with neurodegeneration and the consequent astrogliosis in TLE(HS).


### 4.1. Apoptotic Systems: Ligands and Receptors

#### 4.1.1. The TNF-TNFRSF1A Axis

There are few clinical studies on the TNF system and its effects on epilepsy in spite of intense investigation in animals. Several models indicate that seizures induce the TNF expression in the brain [2, 11–14] although some have shown no important TNF alterations in plasma or CSF after different kinds of seizures [15–18]. In patients, Sinha et al. detected increased serum levels of TNF and other cytokines in several epilepsy syndromes [19]. Our results for TLE(HS) patients differ from those on seizure models only by the fact that theTNF mRNA increase does not seem to be transiently enhanced. Some patients had their last seizure several days before the surgery, implying that the highTNF expression levels were happening often, suggesting that chronic hippocampal inflammation could be intrinsic to refractory TLE(HS).The most controversial evidence on the TNF role in epilepsy was raised when Balosso et al. reported that intrahippocampal injection of murine-recombinant TNF in mice potently prevented seizures [20]. Moreover, transgenic mice overexpressing TNF by astrocytes showed shorter seizures, whereas deficient mice for TNF receptors had prolonged seizures [20]. The dichotomic effect of TNF on seizures may be related to the tissue microenvironment, including the cellular source (neuronal versus glial) of TNF release, the extent of TNF increase, its concentration and persistence in tissue, and action through its two receptors expressed by the targeted cells [14, 20, 21].In the hippocampus, TNF is able to activate its two receptors (TNFRSF1A and TNFRSF1B) to regulate cell-signaling pathways [22, 23]. TNFRSF1A is ubiquitously expressed in human tissues and is the principal signaling receptor for TNF. A cytoplasmic death domain, required for apoptotic signaling pathways and NFkB activation, is present in this major receptor. TNFRSF1B does not contain a death domain and actuates in restricted biological processes, being mainly expressed in immune cells. Through intracellular adaptors called TRAFs (TNF Receptor-Associated Factors) associated with this receptor, JNK (c-Jun N-terminal kinase) is activated during the cell survival induction through activation of NIK (NFkB-inducing kinase), a downstream target of TRAF2. Thus, TNFRSF1A has been involved in apoptosis activation, whereas TNFRSF1B is implicated with activation of the NFkB system [24–26]. Likewise, seizure model studies imply that the TNFRSF1A pathway is associated with deleterious effects and that the TNFRSF1B pathway is related to anticonvulsive outcomes [14, 27].Our hippocampal RT-qPCR results showed the upregulation of both TNF receptors in TLE(HS) patients (Figure2). The deleterious consequences of TNFRSF1A action are well-known; however, for TNFRSF1B, consequences are still unclear. TNFRSF1B could be triggered as a survival mechanism to compensate for the extensive neuronal cell death found in epilepsy-associated HS or its expression could enable the harmful consequences of TNFRSF1A activation [28]. These authors demonstrated that TNFRSF1B significantly decreased the TNF concentration required for cell death without the generation of an intracellular signal. Instead, TNFRSF1B modulated the rate of TNF association with TNFRSF1A, possibly by increasing the local concentration of TNF at the cell surface through rapid ligand association and dissociation. Functional experiments are necessary to verify this finding in brain cells and clarify the role of TNFRSF1B in TLE(HS). Furthermore, these authors proposed that other cell-surface receptors, such as NGFR, may utilize an analogous “ligand passing” mechanism. Our array results showed the upregulation ofNGFR (3.53-fold). Increased expression of NGFR in hippocampal neurons of TLE patients has already been described [29].


#### 4.1.2. The FAS-FASLG Axis

FASLG triggers apoptosis by binding to FAS [30]. Our finding showed the upregulation of bothFAS (1.65-fold) andFASLG (5.46-fold), which represents an important apoptotic system scarcely investigated in clinical cases. Only one study reported an augmentation of FAS in the sclerotic hippocampus from TLE patients [31]. In animals, seizures induced a significant augmentation in FAS expression within the ipsilateral hippocampus from 4 to 24 h after levels returned to baseline [32]. Similarly, increased expression of bothFas mRNA and protein were evident in the adult rat brain from 4 h to 5 days after the onset of kainic acid-induced seizures and neurons with increased FAS expression were also immunoreactive for TP53 [33]. Induced by kainate, FASLG expression increased rapidly at 6 h and returned to the basal level at 3 days in CA1 and CA3/DG (dentate gyrus) hippocampal regions [30, 34].FASLG was the second most upregulated gene according to our results (Figure 1). Considering the chronic status of our patients, this cytokine does not appear to have a transient expression in pharmacoresistant TLE(HS) and might contribute to neuronal loss, being the FAS-FASLG pathway an interesting target for pharmacological studies. In addition, we found thatTNFRSF6B was also overregulated in TLE(HS) patients (2.54-fold). The encoded protein byTNFRSF6B is assumed to play a regulatory role in suppressing FASLG-mediated cell death. It acts as a decoy receptor that competes with death receptors for ligand binding [35] (Figure 3). We have not found any studies regarding the association between TNFRSF6B expression and epilepsy.


#### 4.1.3. The TNFSF10-TNFRSF10A/B Axis

Besides apoptosis mediated by TNF and FASLG and its receptors, TNFSF10 is another potent inducer of apoptosis [36, 37]. Both apoptosis-inducing and nonapoptosis-inducing membrane-bound receptors have been described for TNFSF10. Only TNFRSF10A and TNFRSF10B are able to generate a death signal [38, 39], while TNFRSF10C and TNFRSF10D are truncated and have been proposed to function as decoy receptors by binding TNFSF10 without producing a death signal, thereby inhibiting apoptosis [39, 40]. Our results on gene expression accentuate the importance of TNFSF10 (2.50-fold) and its upregulated receptors (Figure 1). They have never been quantified by RT-qPCR in human TLE hippocampal samples. In brain tissues from TLE patients, Dörr and colleagues did not detect the expression of TNFSF10, but both apoptosis-inducing and non-apoptosis-inducing receptors were expressed on neurons, astrocytes, and oligodendrocytes, which indicate their possible susceptibility to TNFSF10-mediated apoptosis [41]. On the other hand, a significant increase on TNFSF10 expression in both patients and animals (seizure model) has been reported [42]. In accord with our results, it is conceivable that there is an important action of TNFSF10 and its receptors in TLE(HS)-associated neuronal apoptosis. The expression and regulation of these receptors might be crucial for death or survival of an individual cell, since both apoptosis-mediating and apoptosis-blocking receptors were present on the different brain parenchymal cells [37, 41]. Our data per se shows an overview on this apoptotic system and is complemented by the two previously discussed studies on proteins.


### 4.2. Apoptotic Mediators: Caspases and TP53

We found elevated mRNA levels forCASP7,CASP8, andCASP9 in our TLE(HS) samples (Table 1 and Figure 1). This finding extends and reinforces protein data from seizure models and human epileptogenic tissue studies, which have reported a deregulated expression of caspases [32, 43–46]. It is well-known that sequential activation of caspases plays a central role in the execution phase of cell apoptosis.CASP7 is an effector, responsible for cleaving important apoptotic intracellular substrates. Yamamoto et al. found X-linked inhibitor of apoptosis (XIAP) binding CASP7 in TLE brain, suggesting ongoing antiapoptotic responses, which might be impeding caspases from inducing apoptosis [46]. XIAP can only bind activated CASP7 to modulate its activity [47], and XIAP expression is regulated after experimental seizures [48]. Their finding reinforces the evidence for active CASP7 in the TLE hippocampus. CASP8 is a key initiator of apoptosis via death receptor-mediated pathways, capable of inducing apoptosis by directly processing executioner caspases [32]. In a seizure model, its inhibition significantly reduced neuronal apoptosis, accompanied by a decrease of tBID (truncated BID), cleaved CASP9, and cytosol cytochrome c [45]. Our results are in agreement with the studies mentioned and emphasize the importance of CASP7 and CASP8 in TLE(HS) (Figure 3).ATp53 overexpression occurred along with excitotoxicity in an adult rat brain within hours after systemic administration of glutamate analogue kainic acid [49]. Years later and after several other reports on altered TP53 expression in seizure models, including the already mentioned study of Tan and colleagues [33], Xu et al. found TP53 positive cells in the sclerotic hippocampus from TLE patients [31]. In the same year, Engel and colleagues detected significantly higher levels of TP53 by Western blotting in hippocampal tissues from TLE patients [50]. Our result on the elevatedTP53 mRNA level extends and reinforces this data. It is still unclear if TP53 could function as a potential target for protection in seizure-induced neuronal death since TP53 regulates a large number of genes, which would need to be carefully evaluated [31].


### 4.3. Subunits and Regulators of the Transcription Factor NFkB

As previously reported, we found thatNFKB1 was upregulated in TLE(HS) patients [8]. In the present study, our array results showed thatNFKB1 was 1.5-fold more expressed than controls. Several other genes related to the NFkB complex, such asIKBKB (1.96-fold),IKBKG (1.65-fold),NFKB2 (3.21-fold),NFKBIA (2.36-fold), andRELA (2.02-fold) also showed an increased expression (Figure 1). Taken together, our finding clearly emphasizes the NFkB involvement in TLE(HS) physiopathology (Figure 3). In addition, protein or mRNA expression data on those molecules is scarce, even from seizure models.A number of signal transduction events, initiated by inflammation, immunity, differentiation, cell growth, tumorigenesis, and apoptosis, converge on NFkB activation [51]. This pleiotropic transcription factor, present in practically all cell types, is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL, and NFKB2/p52. The heterodimeric p65-p50 complex appears to be the most common. NFKBIA and NFKBIB (I-kappa-B proteins) inhibit the NFkB complex by trapping it in the cytoplasm [51]. The kinases IKBKA and IKBKB mark I-kappa-B proteins for destruction via the ubiquitination pathway, thereby allowing activation of the NFkB complex. IKBKG is a regulatory subunit of the inhibitor of kappa B kinase (IKK) core complex which phosphorylates NFkB inhibitors, leading to the dissociation of the inhibitor/NFkB complex and ultimately the degradation of the inhibitor [51]. Our finding shows that there is a disturbed expression of activators and repressors of the NFkB complex. Further studies are necessary to understand the actual role of NFkB in TLE(HS).


## 4.1. Apoptotic Systems: Ligands and Receptors

### 4.1.1. The TNF-TNFRSF1A Axis

There are few clinical studies on the TNF system and its effects on epilepsy in spite of intense investigation in animals. Several models indicate that seizures induce the TNF expression in the brain [2, 11–14] although some have shown no important TNF alterations in plasma or CSF after different kinds of seizures [15–18]. In patients, Sinha et al. detected increased serum levels of TNF and other cytokines in several epilepsy syndromes [19]. Our results for TLE(HS) patients differ from those on seizure models only by the fact that theTNF mRNA increase does not seem to be transiently enhanced. Some patients had their last seizure several days before the surgery, implying that the highTNF expression levels were happening often, suggesting that chronic hippocampal inflammation could be intrinsic to refractory TLE(HS).The most controversial evidence on the TNF role in epilepsy was raised when Balosso et al. reported that intrahippocampal injection of murine-recombinant TNF in mice potently prevented seizures [20]. Moreover, transgenic mice overexpressing TNF by astrocytes showed shorter seizures, whereas deficient mice for TNF receptors had prolonged seizures [20]. The dichotomic effect of TNF on seizures may be related to the tissue microenvironment, including the cellular source (neuronal versus glial) of TNF release, the extent of TNF increase, its concentration and persistence in tissue, and action through its two receptors expressed by the targeted cells [14, 20, 21].In the hippocampus, TNF is able to activate its two receptors (TNFRSF1A and TNFRSF1B) to regulate cell-signaling pathways [22, 23]. TNFRSF1A is ubiquitously expressed in human tissues and is the principal signaling receptor for TNF. A cytoplasmic death domain, required for apoptotic signaling pathways and NFkB activation, is present in this major receptor. TNFRSF1B does not contain a death domain and actuates in restricted biological processes, being mainly expressed in immune cells. Through intracellular adaptors called TRAFs (TNF Receptor-Associated Factors) associated with this receptor, JNK (c-Jun N-terminal kinase) is activated during the cell survival induction through activation of NIK (NFkB-inducing kinase), a downstream target of TRAF2. Thus, TNFRSF1A has been involved in apoptosis activation, whereas TNFRSF1B is implicated with activation of the NFkB system [24–26]. Likewise, seizure model studies imply that the TNFRSF1A pathway is associated with deleterious effects and that the TNFRSF1B pathway is related to anticonvulsive outcomes [14, 27].Our hippocampal RT-qPCR results showed the upregulation of both TNF receptors in TLE(HS) patients (Figure2). The deleterious consequences of TNFRSF1A action are well-known; however, for TNFRSF1B, consequences are still unclear. TNFRSF1B could be triggered as a survival mechanism to compensate for the extensive neuronal cell death found in epilepsy-associated HS or its expression could enable the harmful consequences of TNFRSF1A activation [28]. These authors demonstrated that TNFRSF1B significantly decreased the TNF concentration required for cell death without the generation of an intracellular signal. Instead, TNFRSF1B modulated the rate of TNF association with TNFRSF1A, possibly by increasing the local concentration of TNF at the cell surface through rapid ligand association and dissociation. Functional experiments are necessary to verify this finding in brain cells and clarify the role of TNFRSF1B in TLE(HS). Furthermore, these authors proposed that other cell-surface receptors, such as NGFR, may utilize an analogous “ligand passing” mechanism. Our array results showed the upregulation ofNGFR (3.53-fold). Increased expression of NGFR in hippocampal neurons of TLE patients has already been described [29].


### 4.1.2. The FAS-FASLG Axis

FASLG triggers apoptosis by binding to FAS [30]. Our finding showed the upregulation of bothFAS (1.65-fold) andFASLG (5.46-fold), which represents an important apoptotic system scarcely investigated in clinical cases. Only one study reported an augmentation of FAS in the sclerotic hippocampus from TLE patients [31]. In animals, seizures induced a significant augmentation in FAS expression within the ipsilateral hippocampus from 4 to 24 h after levels returned to baseline [32]. Similarly, increased expression of bothFas mRNA and protein were evident in the adult rat brain from 4 h to 5 days after the onset of kainic acid-induced seizures and neurons with increased FAS expression were also immunoreactive for TP53 [33]. Induced by kainate, FASLG expression increased rapidly at 6 h and returned to the basal level at 3 days in CA1 and CA3/DG (dentate gyrus) hippocampal regions [30, 34].FASLG was the second most upregulated gene according to our results (Figure 1). Considering the chronic status of our patients, this cytokine does not appear to have a transient expression in pharmacoresistant TLE(HS) and might contribute to neuronal loss, being the FAS-FASLG pathway an interesting target for pharmacological studies. In addition, we found thatTNFRSF6B was also overregulated in TLE(HS) patients (2.54-fold). The encoded protein byTNFRSF6B is assumed to play a regulatory role in suppressing FASLG-mediated cell death. It acts as a decoy receptor that competes with death receptors for ligand binding [35] (Figure 3). We have not found any studies regarding the association between TNFRSF6B expression and epilepsy.


### 4.1.3. The TNFSF10-TNFRSF10A/B Axis

Besides apoptosis mediated by TNF and FASLG and its receptors, TNFSF10 is another potent inducer of apoptosis [36, 37]. Both apoptosis-inducing and nonapoptosis-inducing membrane-bound receptors have been described for TNFSF10. Only TNFRSF10A and TNFRSF10B are able to generate a death signal [38, 39], while TNFRSF10C and TNFRSF10D are truncated and have been proposed to function as decoy receptors by binding TNFSF10 without producing a death signal, thereby inhibiting apoptosis [39, 40]. Our results on gene expression accentuate the importance of TNFSF10 (2.50-fold) and its upregulated receptors (Figure 1). They have never been quantified by RT-qPCR in human TLE hippocampal samples. In brain tissues from TLE patients, Dörr and colleagues did not detect the expression of TNFSF10, but both apoptosis-inducing and non-apoptosis-inducing receptors were expressed on neurons, astrocytes, and oligodendrocytes, which indicate their possible susceptibility to TNFSF10-mediated apoptosis [41]. On the other hand, a significant increase on TNFSF10 expression in both patients and animals (seizure model) has been reported [42]. In accord with our results, it is conceivable that there is an important action of TNFSF10 and its receptors in TLE(HS)-associated neuronal apoptosis. The expression and regulation of these receptors might be crucial for death or survival of an individual cell, since both apoptosis-mediating and apoptosis-blocking receptors were present on the different brain parenchymal cells [37, 41]. Our data per se shows an overview on this apoptotic system and is complemented by the two previously discussed studies on proteins.


## 4.1.1. The TNF-TNFRSF1A Axis

There are few clinical studies on the TNF system and its effects on epilepsy in spite of intense investigation in animals. Several models indicate that seizures induce the TNF expression in the brain [2, 11–14] although some have shown no important TNF alterations in plasma or CSF after different kinds of seizures [15–18]. In patients, Sinha et al. detected increased serum levels of TNF and other cytokines in several epilepsy syndromes [19]. Our results for TLE(HS) patients differ from those on seizure models only by the fact that theTNF mRNA increase does not seem to be transiently enhanced. Some patients had their last seizure several days before the surgery, implying that the highTNF expression levels were happening often, suggesting that chronic hippocampal inflammation could be intrinsic to refractory TLE(HS).The most controversial evidence on the TNF role in epilepsy was raised when Balosso et al. reported that intrahippocampal injection of murine-recombinant TNF in mice potently prevented seizures [20]. Moreover, transgenic mice overexpressing TNF by astrocytes showed shorter seizures, whereas deficient mice for TNF receptors had prolonged seizures [20]. The dichotomic effect of TNF on seizures may be related to the tissue microenvironment, including the cellular source (neuronal versus glial) of TNF release, the extent of TNF increase, its concentration and persistence in tissue, and action through its two receptors expressed by the targeted cells [14, 20, 21].In the hippocampus, TNF is able to activate its two receptors (TNFRSF1A and TNFRSF1B) to regulate cell-signaling pathways [22, 23]. TNFRSF1A is ubiquitously expressed in human tissues and is the principal signaling receptor for TNF. A cytoplasmic death domain, required for apoptotic signaling pathways and NFkB activation, is present in this major receptor. TNFRSF1B does not contain a death domain and actuates in restricted biological processes, being mainly expressed in immune cells. Through intracellular adaptors called TRAFs (TNF Receptor-Associated Factors) associated with this receptor, JNK (c-Jun N-terminal kinase) is activated during the cell survival induction through activation of NIK (NFkB-inducing kinase), a downstream target of TRAF2. Thus, TNFRSF1A has been involved in apoptosis activation, whereas TNFRSF1B is implicated with activation of the NFkB system [24–26]. Likewise, seizure model studies imply that the TNFRSF1A pathway is associated with deleterious effects and that the TNFRSF1B pathway is related to anticonvulsive outcomes [14, 27].Our hippocampal RT-qPCR results showed the upregulation of both TNF receptors in TLE(HS) patients (Figure2). The deleterious consequences of TNFRSF1A action are well-known; however, for TNFRSF1B, consequences are still unclear. TNFRSF1B could be triggered as a survival mechanism to compensate for the extensive neuronal cell death found in epilepsy-associated HS or its expression could enable the harmful consequences of TNFRSF1A activation [28]. These authors demonstrated that TNFRSF1B significantly decreased the TNF concentration required for cell death without the generation of an intracellular signal. Instead, TNFRSF1B modulated the rate of TNF association with TNFRSF1A, possibly by increasing the local concentration of TNF at the cell surface through rapid ligand association and dissociation. Functional experiments are necessary to verify this finding in brain cells and clarify the role of TNFRSF1B in TLE(HS). Furthermore, these authors proposed that other cell-surface receptors, such as NGFR, may utilize an analogous “ligand passing” mechanism. Our array results showed the upregulation ofNGFR (3.53-fold). Increased expression of NGFR in hippocampal neurons of TLE patients has already been described [29].


## 4.1.2. The FAS-FASLG Axis

FASLG triggers apoptosis by binding to FAS [30]. Our finding showed the upregulation of bothFAS (1.65-fold) andFASLG (5.46-fold), which represents an important apoptotic system scarcely investigated in clinical cases. Only one study reported an augmentation of FAS in the sclerotic hippocampus from TLE patients [31]. In animals, seizures induced a significant augmentation in FAS expression within the ipsilateral hippocampus from 4 to 24 h after levels returned to baseline [32]. Similarly, increased expression of bothFas mRNA and protein were evident in the adult rat brain from 4 h to 5 days after the onset of kainic acid-induced seizures and neurons with increased FAS expression were also immunoreactive for TP53 [33]. Induced by kainate, FASLG expression increased rapidly at 6 h and returned to the basal level at 3 days in CA1 and CA3/DG (dentate gyrus) hippocampal regions [30, 34].FASLG was the second most upregulated gene according to our results (Figure 1). Considering the chronic status of our patients, this cytokine does not appear to have a transient expression in pharmacoresistant TLE(HS) and might contribute to neuronal loss, being the FAS-FASLG pathway an interesting target for pharmacological studies. In addition, we found thatTNFRSF6B was also overregulated in TLE(HS) patients (2.54-fold). The encoded protein byTNFRSF6B is assumed to play a regulatory role in suppressing FASLG-mediated cell death. It acts as a decoy receptor that competes with death receptors for ligand binding [35] (Figure 3). We have not found any studies regarding the association between TNFRSF6B expression and epilepsy.


## 4.1.3. The TNFSF10-TNFRSF10A/B Axis

Besides apoptosis mediated by TNF and FASLG and its receptors, TNFSF10 is another potent inducer of apoptosis [36, 37]. Both apoptosis-inducing and nonapoptosis-inducing membrane-bound receptors have been described for TNFSF10. Only TNFRSF10A and TNFRSF10B are able to generate a death signal [38, 39], while TNFRSF10C and TNFRSF10D are truncated and have been proposed to function as decoy receptors by binding TNFSF10 without producing a death signal, thereby inhibiting apoptosis [39, 40]. Our results on gene expression accentuate the importance of TNFSF10 (2.50-fold) and its upregulated receptors (Figure 1). They have never been quantified by RT-qPCR in human TLE hippocampal samples. In brain tissues from TLE patients, Dörr and colleagues did not detect the expression of TNFSF10, but both apoptosis-inducing and non-apoptosis-inducing receptors were expressed on neurons, astrocytes, and oligodendrocytes, which indicate their possible susceptibility to TNFSF10-mediated apoptosis [41]. On the other hand, a significant increase on TNFSF10 expression in both patients and animals (seizure model) has been reported [42]. In accord with our results, it is conceivable that there is an important action of TNFSF10 and its receptors in TLE(HS)-associated neuronal apoptosis. The expression and regulation of these receptors might be crucial for death or survival of an individual cell, since both apoptosis-mediating and apoptosis-blocking receptors were present on the different brain parenchymal cells [37, 41]. Our data per se shows an overview on this apoptotic system and is complemented by the two previously discussed studies on proteins.


## 4.2. Apoptotic Mediators: Caspases and TP53

We found elevated mRNA levels forCASP7,CASP8, andCASP9 in our TLE(HS) samples (Table 1 and Figure 1). This finding extends and reinforces protein data from seizure models and human epileptogenic tissue studies, which have reported a deregulated expression of caspases [32, 43–46]. It is well-known that sequential activation of caspases plays a central role in the execution phase of cell apoptosis.CASP7 is an effector, responsible for cleaving important apoptotic intracellular substrates. Yamamoto et al. found X-linked inhibitor of apoptosis (XIAP) binding CASP7 in TLE brain, suggesting ongoing antiapoptotic responses, which might be impeding caspases from inducing apoptosis [46]. XIAP can only bind activated CASP7 to modulate its activity [47], and XIAP expression is regulated after experimental seizures [48]. Their finding reinforces the evidence for active CASP7 in the TLE hippocampus. CASP8 is a key initiator of apoptosis via death receptor-mediated pathways, capable of inducing apoptosis by directly processing executioner caspases [32]. In a seizure model, its inhibition significantly reduced neuronal apoptosis, accompanied by a decrease of tBID (truncated BID), cleaved CASP9, and cytosol cytochrome c [45]. Our results are in agreement with the studies mentioned and emphasize the importance of CASP7 and CASP8 in TLE(HS) (Figure 3).ATp53 overexpression occurred along with excitotoxicity in an adult rat brain within hours after systemic administration of glutamate analogue kainic acid [49]. Years later and after several other reports on altered TP53 expression in seizure models, including the already mentioned study of Tan and colleagues [33], Xu et al. found TP53 positive cells in the sclerotic hippocampus from TLE patients [31]. In the same year, Engel and colleagues detected significantly higher levels of TP53 by Western blotting in hippocampal tissues from TLE patients [50]. Our result on the elevatedTP53 mRNA level extends and reinforces this data. It is still unclear if TP53 could function as a potential target for protection in seizure-induced neuronal death since TP53 regulates a large number of genes, which would need to be carefully evaluated [31].


## 4.3. Subunits and Regulators of the Transcription Factor NFkB

As previously reported, we found thatNFKB1 was upregulated in TLE(HS) patients [8]. In the present study, our array results showed thatNFKB1 was 1.5-fold more expressed than controls. Several other genes related to the NFkB complex, such asIKBKB (1.96-fold),IKBKG (1.65-fold),NFKB2 (3.21-fold),NFKBIA (2.36-fold), andRELA (2.02-fold) also showed an increased expression (Figure 1). Taken together, our finding clearly emphasizes the NFkB involvement in TLE(HS) physiopathology (Figure 3). In addition, protein or mRNA expression data on those molecules is scarce, even from seizure models.A number of signal transduction events, initiated by inflammation, immunity, differentiation, cell growth, tumorigenesis, and apoptosis, converge on NFkB activation [51]. This pleiotropic transcription factor, present in practically all cell types, is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL, and NFKB2/p52. The heterodimeric p65-p50 complex appears to be the most common. NFKBIA and NFKBIB (I-kappa-B proteins) inhibit the NFkB complex by trapping it in the cytoplasm [51]. The kinases IKBKA and IKBKB mark I-kappa-B proteins for destruction via the ubiquitination pathway, thereby allowing activation of the NFkB complex. IKBKG is a regulatory subunit of the inhibitor of kappa B kinase (IKK) core complex which phosphorylates NFkB inhibitors, leading to the dissociation of the inhibitor/NFkB complex and ultimately the degradation of the inhibitor [51]. Our finding shows that there is a disturbed expression of activators and repressors of the NFkB complex. Further studies are necessary to understand the actual role of NFkB in TLE(HS).


## 5. Conclusions

We have demonstrated the upregulation of various genes associated with the apoptosis through death receptor signaling in the hippocampus from TLE(HS) patients. The expression of the vast majority of these genes was studied for the first time in hippocampal human samples despite previous protein results, mainly from seizure models. Our data reveals that both TNF receptor genes (TNFRSF1A andTNFRSF1B) are overexpressed in patients. As key factors in the TNF-induced apoptosis, they may play a crucial role in hippocampal neuroinflammation and neurodegeneration.Additionally, our results clearly suggest that three different death receptor apoptotic systems may be associated with the maintenance and progression of TLE-associated HS: (1) TNF-TNFRSF1A, (2) FASLG-FAS, and (3) TNFSF10-TNFRSF10A/B. Their effects on epilepsy are still scarcely comprehended. Other targets, such as the NFkB subunits and regulators or the decoy receptor of FAS, TNFRSF6B, whose gene upregulation has never been associated with epilepsy, should be investigated. The understanding of these signaling pathways is essential for the development of new antiepileptic drugs and opens several possible avenues of research that will help us to understand the complex pathophysiology in HS.



---

*Source: 8290562-2016-02-23.xml*